PLAC9 Activators consist of a diverse array of chemical compounds that indirectly promote the functional activity of PLAC9 through several cellular signaling pathways. Forskolin, known for its ability to enhance adenylate cyclase activity and thus increase cAMP levels, indirectly elevates PLAC9 activity by activating PKA, which may phosphorylate PLAC9 if it is amenable to this post-translational modification. Similarly, PMA activates PKC, another kinase that could potentially phosphorylate PLAC9, leading to its activation. Ionomycin, by raising intracellular calcium levels, and A23187 (Calcimycin), a selective calcium ionophore, both potentiate the activation of calcium-dependent protein kinases that might phosphorylate and activate PLAC9. db-cAMP, as a cAMP analog, mimics the action of Forskolin and activates PKA, which may target PLAC9. Sodium orthovanadate, by inhibiting protein tyrosine phosphatases, and hydrogen peroxide, as amodulator of kinase and phosphatase activity, contribute to the enhancement of PLAC9 activation by potentially increasing its phosphorylated state.
The modulation of kinase activity by Epigallocatechin gallate (EGCG) and the increase in intracellular calcium by A23187 (Calcimycin) may also lead to enhanced PLAC9 function by altering the kinase and phosphatase balance in favor of PLAC9 activation. Oleic acid's integration into cellular membranes could influence membrane-associated signaling, which in turn could lead to the activation of PLAC9. Additionally, NADPH, by serving as a substrate for NADPH oxidases that produce reactive oxygen species, may modulate signaling pathways that enhance PLAC9 activity. Lastly, Zinc sulfate is crucial for the proper functioning of various kinases; hence, an adequate zinc level ensures that zinc-dependent kinases can phosphorylate and activate PLAC9 efficiently. Each of these chemicals, by leveraging different aspects of cellular signaling and enzyme regulation, serves to enhance the activity of PLAC9, thereby orchestrating a concerted increase in its functional engagement within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin raises intracellular cAMP levels, which can lead to activation of PKA. PKA is known to phosphorylate a variety of proteins, potentially enhancing the functional activity of PLAC9. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
PMA is a diacylglycerol analogue that activates protein kinase C (PKC). PKC activation can lead to phosphorylation of proteins and downstream signaling pathways, which may increase PLAC9 activity. | ||||||
Ionomycin, free acid | 56092-81-0 | sc-263405 sc-263405A | 1 mg 5 mg | $94.00 $259.00 | 2 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels, activating calcium-dependent signaling pathways that could upregulate PLAC9 activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
EGCG inhibits certain types of kinases, which may relieve negative regulatory effects on pathways involving PLAC9, leading to its enhanced activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. By reducing PI3K activity, it may alter the balance of downstream signaling pathways in favor of those that activate PLAC9. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
S1P interacts with its receptors to activate intracellular signaling cascades, potentially enhancing the pathways that upregulate PLAC9 activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase (SERCA), leading to increased cytosolic calcium levels and potentially enhancing the pathways that activate PLAC9. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a MEK inhibitor that may shift the balance of MAPK pathway signaling, potentially favoring the activation of PLAC9. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor that may reduce competitive signaling and enhance pathways that lead to PLAC9 activation. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $54.00 $128.00 $199.00 $311.00 | 23 | |
A23187 is a calcium ionophore that increases intracellular calcium levels, similar to ionomycin, and may enhance the signaling pathways that upregulate PLAC9 activity. | ||||||